Tevogen Bio Highlights the Future of AI-Driven Drug Development in Fireside Chat with Microsoft During the J.P. Morgan Healthcare Conference

Company Overview - Tevogen Bio is a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for infectious diseases and cancers [1] - The company is leveraging artificial intelligence (AI) and machine learning (ML) through its TevogenAI platform to achieve cost and time efficiencies in drug development [1] - Tevogen Bio focuses on CD8+ cytotoxic T lymphocytes to develop precision T cell therapies for infectious diseases, cancers, and neurological disorders [6] - The company has reported positive safety data from its proof-of-concept clinical trial and owns key intellectual property assets, including three granted patents and nine pending US patents [6] - Tevogen Bio is led by a team of experienced industry leaders and scientists with expertise in drug development and global product launches [7] AI in Drug Development - AI-driven modeling and simulation are drastically reducing the time required to identify and develop drug candidates, with tasks that previously took thousands of years now completed in months [2] - Generative AI and multimodal data approaches are being used to process diverse data sources, such as imaging, genomics, and electronic health records, to reveal novel insights [3] - AI serves as a powerful query engine on top of foundation models, enabling seamless interpretation and conversion of complex data into clinically relevant results [3] - Tevogen Bio is creating curated datasets supported by wet-lab research to fuel the creation of reliable foundational AI models [4] - Clean and annotated datasets are critical for AI to function effectively, with strong data governance and privacy-preserving techniques like federated learning being emphasized [4] Industry Impact and Vision - AI is described as the next industrial revolution and a transformative force in drug development, with the potential to bridge medical science and technology [5] - The company is committed to advancing affordable medical innovation through AI, focusing on patient accessibility and disruptive business models [5][6] - Responsible AI development practices, including bias mitigation, transparency, and continuous oversight, are vital for equitable and safe adoption in healthcare [4] - Tevogen Bio believes that accessible personalized therapeutics and innovative business models are essential for sustaining medical innovation in the current healthcare era [7]